Proteostasis Adds Targets, Drugs From Harvard

Xconomy Boston — 

Proteostasis Therapeutics, the Cambridge, MA-based company seeking to keep proteins in balance to fight neurodegenerative diseases, said today it has obtained two exclusive technology licenses from Harvard University. The licenses pertain to the ubiquitin-proteosome pathway, and include biological targets and small-molecule drug candidates. Proteostasis, founded by Healthcare Ventures in Boston with technology from The Scripps Research Institute in San Diego, isn’t disclosing financial terms of the deal. The new batch of intellectual property comes from the Harvard labs of Daniel Finley, Randall King, and Alfred Goldberg, the company said.